TidalSense, a Cambridge‑based health‑technology firm, announced a €16.6 million financing round on July 24 2026.The capital will be used to expand commercial rollout of its handheld AI diagnostic device for chronic obstructive pulmonary disease (COPD).
The startup TidalSense, formerly known as Cambridge Respiratory Innovations, disclosed on July 24 2026 that it has closed a €16.6 million funding round to advance its artificial‑intelligence (AI) respiratory diagnostic platform [1]. The announcement was made from the company’s headquarters in Cambridge, United Kingdom [1].
The round was led by a consortium of private investors; the specific firms were not identified in the public statements [1]. TidalSense’s executive team, including CEO Dr. Emily Carter, confirmed that the new capital will accelerate the deployment of its N‑Tidal Diagnose handheld device across NHS trusts and private clinics [3]. The company’s AI models have been trained on more than 2.5 million patient breaths, enabling rapid detection of lung disease markers [3].
Funding Round Details and Investor Participation
The €16.6 million financing comprises equity and convertible‑note components, according to the company’s press release [1]. While the identities of the lead investors were not disclosed, the statement noted participation from existing backers and new strategic partners focused on digital health [2]. The funding round follows a prior seed investment of €5 million secured in 2024, reflecting continued investor confidence in AI‑driven diagnostics [1].
TidalSense’s board approved the allocation of the new capital to three primary areas: scaling manufacturing of the N‑Tidal Diagnose device, expanding clinical validation studies, and building a sales and support infrastructure in Europe and North America [3]. The company also indicated that part of the funds will support regulatory submissions for CE marking and FDA clearance [2][3].
Funding Round Details and Investor Participation The €16.6 million financing comprises equity and convertible‑note components, according to the company’s press release [1].
Technology Overview and Clinical Application
Cambridge Health‑Tech Startup TidalSense Secures €16.6 Million Funding for AI‑Powered Respiratory Diagnostics
TidalSense’s core technology combines a handheld breath‑analysis sensor with proprietary AI algorithms that interpret respiratory patterns in real time [3]. The N‑Tidal Diagnose device captures a patient’s breath over a 30‑second interval and generates a diagnostic report for COPD within minutes, reducing the typical test duration from 30 minutes to under five minutes [3].
The AI models were trained on a dataset exceeding 2.5 million breath recordings, sourced from NHS hospitals and research collaborations, to ensure robustness across diverse patient populations [3]. Clinical trials conducted in 2025 demonstrated a diagnostic accuracy of 92 % for COPD detection, meeting the performance thresholds required for regulatory approval [1][4]. The device is classified as a Class II medical device under EU MDR guidelines [2].
Maharashtra’s health ministry announced the removal of the compulsory service bond for MBBS graduates, ending a long‑standing requirement that doctors serve in government hospitals for…
The infusion of €16.6 million positions TidalSense to increase the availability of rapid, AI‑assisted COPD screening in primary‑care settings [4]. With nearly two million UK residents diagnosed with COPD, the technology offers a pathway to earlier detection and treatment initiation [3]. Reducing test time can free clinical staff for additional patient encounters, potentially improving throughput in overstretched respiratory clinics [4].
For patients, the handheld device eliminates the need for prolonged spirometry sessions, offering a less invasive and more convenient diagnostic experience [3]. Healthcare providers anticipate that the faster turnaround may support more timely therapeutic decisions, aligning with NHS targets for chronic disease management [1].
The funding also enables TidalSense to pursue international market entry, with planned regulatory submissions in the United States slated for early 2027 [2]. Successful clearance could broaden access to AI‑driven respiratory diagnostics across multiple health systems, influencing standard care pathways for lung disease worldwide [4].
Key Facts
Successful clearance could broaden access to AI‑driven respiratory diagnostics across multiple health systems, influencing standard care pathways for lung disease worldwide [4].
What: TidalSense raised €16.6 million to expand its AI‑powered handheld COPD diagnostic device.
Battery-powered cooling vests, including the ClemaCore model, entered limited release in summer 2026, providing full‑shift active cooling without ice or work interruptions.
NewsNews
